Galectin Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Galectin Therapeutics

16/05/2022 18:23

* Galectin Therapeutics Inc  GALT.OQ  reported a quarterly
adjusted loss of 17 cents​​ per share for the quarter ended in
March. The lone analyst forecast for the quarter was for a loss
of 14 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Galectin Therapeutics Inc's reported EPS for the quarter
was a
loss of 17 cents​.
    * The mean earnings estimate of analysts had risen by
about 30% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Galectin Therapeutics Inc shares had fallen by 15.5% this
quarter and lost 34.3% so far this year.
    * The company reported a quarterly loss of $9.92 million.
    * Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $14.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 05:23 p.m.  ​All
figures in US dollars unless otherwise stated